Treatment options for metastatic melanoma in solid organ transplant recipients

Thuzar M Shin; Tara Gangadhar; Christopher J Miller

doi:10.1016/j.jdcr.2015.09.013

Treatment options for metastatic melanoma in solid organ transplant recipients

JAAD Case Rep. 2015 Nov 24;1(6):S26-8. doi: 10.1016/j.jdcr.2015.09.013. eCollection 2015 Nov.

Authors

Thuzar M Shin¹, Tara Gangadhar², Christopher J Miller¹

Affiliations

¹ Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
² Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

No abstract available

Keywords: CTLA, cytotoxic T-lymphocyte–associated protein 4; FDA, US Food and Drug Administration; IFN-α, interferon alfa; MAPK, mitogen-activated protein kinase; PD-1, programmed death-1; SOTRs, solid organ transplant recipients; immunosuppression; metastatic melanoma; organ transplant; systemic therapy.

Publication types

Case Reports